Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $5.09, for a total value of $15,712.83. Following the completion of the transaction, the chief operating officer now directly owns 109,241 shares of the company’s stock, valued at $556,036.69. This represents a 2.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The stock was sold at an average price of $5.65, for a total value of $36,725.00.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR traded up $0.14 during midday trading on Wednesday, reaching $5.19. 398,045 shares of the company’s stock traded hands, compared to its average volume of 397,579. The company has a market cap of $283.51 million, a price-to-earnings ratio of 7.31 and a beta of 0.93. Voyager Therapeutics, Inc. has a one year low of $5.03 and a one year high of $10.66. The stock has a 50 day moving average of $6.04 and a 200 day moving average of $6.76.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the company posted ($0.59) earnings per share. Sell-side analysts predict that Voyager Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its position in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics in the third quarter worth about $74,000. Victory Capital Management Inc. increased its position in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after buying an additional 1,630 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Voyager Therapeutics in the second quarter worth about $128,000. Finally, Verition Fund Management LLC purchased a new stake in Voyager Therapeutics in the third quarter worth about $216,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald assumed coverage on Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.